Opinion|Videos|April 4, 2025
Emerging Therapeutic Areas for Bispecific Antibodies
Experts discuss the most promising applications of bispecifics in solid tumors and other emerging therapeutic areas.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are the most promising applications of bispecifics in solid tumors and other emerging therapeutic areas?
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Advertisement
Advertisement
Trending on AJMC
1
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
2
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
3
J&J Oncology Care Index Finds Community Innovation Adoption Gap
4
Specialty Pharmacy Leaders to Convene for NASP inSPire2026
5